PA
CGON icon

Profund Advisors’s CG Oncology CGON Stock Holding History

Profund Advisors’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85M Sell
25,972
-4,716
-15% -$308K 0.05% 216
2026
Q1 		$2.08M Sell
30,688
-8,631
-22% -$489K 0.08% 193
2025
Q4 		$1.63M Buy
39,319
+25,568
+186% +$1.06M 0.05% 256
2025
Q3 		$554K Sell
13,751
-3,234
-19% -$94K 0.02% 479
2025
Q2 		$442K Buy
16,985
+1,841
+12% +$44.4K 0.02% 505
2025
Q1 		$371K Sell
15,144
-371
-2% -$10.4K 0.02% 577
2024
Q4 		$445K Sell
15,515
-342
-2% -$11.7K 0.02% 575
2024
Q3 		$598K Buy
15,857
+6,344
+67% +$222K 0.02% 457
2024
Q2 		$300K Buy
+9,513
New +$330K 0.01% 722

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Profund Advisors's CGON Position: Q2 2026 in Review

Profund Advisors reduced its CG Oncology (CGON) stake by 15% in Q2 2026, selling an estimated $308K and leaving 25,972 shares worth $1.85M. The position accounts for 0.05% of the portfolio, ranked #216.

Profund Advisors first reported a position in CGON in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.08M in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Profund Advisors held 25,972 shares of CG Oncology worth $1.85M as of Q2 2026.
  • Profund Advisors sold 4,716 CG Oncology shares in Q2 2026, an estimated $308K.
  • CG Oncology made up 0.05% of Profund Advisors's portfolio in Q2 2026, its #216 holding.
  • Profund Advisors first reported a position in CG Oncology in Q2 2024 and has held it in 9 quarters since.
  • Profund Advisors's CG Oncology position peaked at $2.08M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.